Abstract |
Correlates of immune protection from HIV vaccines remain undefined. The first HIV vaccine efficacy trial in the US and Europe VAX004, was designed to assess whether rgp120 envelope subunits ( AIDSVAX B/B, VaxGen) can induce partial or complete protection from HIV-1 infection. No effectiveness in the reduction of either the acquisition of infection or levels of plasma viremia after HIV infection was noted. We found evidence of vaccine-specific CD8+ T cells in volunteers who received the vaccine, regardless of behavioral risk. Surprisingly, the CD8-response is significantly higher in participants who would go on to contract HIV infection. These results suggest that AIDSVAX immunization may boost preexisting immune responses-due to pre- infection exposure, and a vaccine-induced immune profile may serve as a biological marker for HIV susceptibility.
|
Authors | Norman G Jones, Allan DeCamp, Peter Gilbert, Michael L Peterson, Marc Gurwith, Huyen Cao |
Journal | Vaccine
(Vaccine)
Vol. 27
Issue 7
Pg. 1136-40
(Feb 11 2009)
ISSN: 0264-410X [Print] Netherlands |
PMID | 19071176
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- AIDS Vaccines
(immunology)
- Adolescent
- Adult
- CD8-Positive T-Lymphocytes
(immunology)
- Disease Susceptibility
- Europe
- HIV Infections
(immunology, prevention & control)
- Human Experimentation
- Humans
- Middle Aged
- United States
- Viremia
(prevention & control)
- Young Adult
|